001     842598
005     20210129232404.0
024 7 _ |a 10.3390/ph10040099
|2 doi
024 7 _ |a 2128/16733
|2 Handle
024 7 _ |a WOS:000419241100021
|2 WOS
024 7 _ |a altmetric:30640470
|2 altmetric
024 7 _ |a pmid:29258264
|2 pmid
037 _ _ |a FZJ-2018-00811
082 _ _ |a 610
100 1 _ |a Feni, Lucia
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Convenient Preparation of 18F-Labeled Peptide Probes for Potential Claudin-4 PET Imaging
260 _ _ |a Basel
|c 2017
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1516892168_22600
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Since pancreatic cancer is often diagnosed in a late state of cancer development, diagnostic opportunities allowing early disease detection are highly sought after. As such, cancer expression of claudin proteins is markedly dysregulated, making it an attractive target for molecular imaging like positron emission tomography (PET). Claudins are a family of transmembrane proteins that have a pivotal role as members of the tight junctions. In particular, claudin-3 and claudin-4 are frequently overexpressed in pancreatic cancer. 18F-Labeled claudin selective peptides would provide access to a novel kind of imaging tools for pancreatic cancer. In this work we describe the synthesis of the first 18F-labeled probes potentially suitable for PET imaging of claudin-4 expression. These probes were prepared using oxime ligation of 5-[18F]fluoro-5-deoxyribose (5-[18F]FDR) to claudin selective peptides. As a proof-of-principle, one of them, 5-[18F]FDR-Clone 27, was isolated in >98% radiochemical purity and in 15% radiochemical yield (EOB) within 98 min, and with a molar activity of 4.0 GBq/μmol (for 30 MBq of tracer). Moreover, we present first biological data for the prepared 5-FDR-conjugates. These tracers could pave the way for an early diagnosis of pancreatic tumor, and thus improve the outcome of anticancer therapy.
536 _ _ |a 573 - Neuroimaging (POF3-573)
|0 G:(DE-HGF)POF3-573
|c POF3-573
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Omrane, Aymen
|0 P:(DE-Juel1)166553
|b 1
700 1 _ |a Fischer, Moritz
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Zlatopolskiy, Boris
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Neumaier, Bernd
|0 P:(DE-Juel1)166419
|b 4
|e Corresponding author
700 1 _ |a Neundorf, Ines
|0 P:(DE-HGF)0
|b 5
773 _ _ |a 10.3390/ph10040099
|g Vol. 10, no. 4, p. 99 -
|0 PERI:(DE-600)2193542-7
|n 4
|p 99 -
|t Pharmaceuticals
|v 10
|y 2017
|x 1424-8247
856 4 _ |y OpenAccess
|u https://juser.fz-juelich.de/record/842598/files/pharmaceuticals-10-00099.pdf
856 4 _ |y OpenAccess
|x icon
|u https://juser.fz-juelich.de/record/842598/files/pharmaceuticals-10-00099.gif?subformat=icon
856 4 _ |y OpenAccess
|x icon-1440
|u https://juser.fz-juelich.de/record/842598/files/pharmaceuticals-10-00099.jpg?subformat=icon-1440
856 4 _ |y OpenAccess
|x icon-180
|u https://juser.fz-juelich.de/record/842598/files/pharmaceuticals-10-00099.jpg?subformat=icon-180
856 4 _ |y OpenAccess
|x icon-640
|u https://juser.fz-juelich.de/record/842598/files/pharmaceuticals-10-00099.jpg?subformat=icon-640
856 4 _ |y OpenAccess
|x pdfa
|u https://juser.fz-juelich.de/record/842598/files/pharmaceuticals-10-00099.pdf?subformat=pdfa
909 C O |o oai:juser.fz-juelich.de:842598
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)166553
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)166419
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-573
|2 G:(DE-HGF)POF3-500
|v Neuroimaging
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-5-20090406
|k INM-5
|l Nuklearchemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-5-20090406
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21